- Home
- RCS vs THRD Comparison
RCS vs THRD Comparison
Compare RCS & THRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCS
- THRD
- Stock Information
- Founded
- RCS 1994
- THRD 2019
- Country
- RCS United States
- THRD United States
- Employees
- RCS N/A
- THRD N/A
- Industry
- RCS Investment Managers
- THRD Biotechnology: Pharmaceutical Preparations
- Sector
- RCS Finance
- THRD Health Care
- Exchange
- RCS Nasdaq
- THRD Nasdaq
- Market Cap
- RCS 292.8M
- THRD 335.2M
- IPO Year
- RCS N/A
- THRD 2022
- Fundamental
- Price
- RCS $6.54
- THRD $6.00
- Analyst Decision
- RCS
- THRD Strong Buy
- Analyst Count
- RCS 0
- THRD 3
- Target Price
- RCS N/A
- THRD $20.33
- AVG Volume (30 Days)
- RCS 141.1K
- THRD 248.2K
- Earning Date
- RCS 01-01-0001
- THRD 11-07-2024
- Dividend Yield
- RCS 10.12%
- THRD N/A
- EPS Growth
- RCS N/A
- THRD N/A
- EPS
- RCS N/A
- THRD N/A
- Revenue
- RCS N/A
- THRD N/A
- Revenue This Year
- RCS N/A
- THRD N/A
- Revenue Next Year
- RCS N/A
- THRD N/A
- P/E Ratio
- RCS N/A
- THRD N/A
- Revenue Growth
- RCS N/A
- THRD N/A
- 52 Week Low
- RCS $4.51
- THRD $5.60
- 52 Week High
- RCS $6.31
- THRD $16.94
- Technical
- Relative Strength Index (RSI)
- RCS 41.39
- THRD 23.75
- Support Level
- RCS $6.26
- THRD $5.60
- Resistance Level
- RCS $6.50
- THRD $11.78
- Average True Range (ATR)
- RCS 0.32
- THRD 0.89
- MACD
- RCS 0.01
- THRD -0.43
- Stochastic Oscillator
- RCS 41.35
- THRD 6.50
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with this objective.
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.